A multistakeholder call for belzutifan biomarker data in advanced pheochromocytoma and paraganglioma.
The HIF-2α inhibitor belzutifan was recently U.S. Food and Drug Administration (FDA)-approved for advanced pheochromocytoma/paraganglioma. This multistakeholder article calls for clinical-trial genomic correlates and outcome data to clarify efficacy across these molecularly heterogeneous neuroendocrine tumors.
Pheochromocytoma↗